Meet
Debbie Lucas

Debbie Lucas leads client engagements involving the design, implementation, and evaluation of initiatives to transform care practices through the use of tools and processes to support shared decision-making, self-management, care coordination, and guideline-based care.

She works with a broad range of stakeholders including professional organizations, life science companies, and healthcare providers to advance the strategic collection and use of data to improve patient care. This work includes the development and use of quality measures.

Prior to joining Avalere, Debbie was the director of Clinical Quality and Consulting at DocSite implementing registries in health systems to support point-of-care decision-making, population management, and quality measure reporting. She spent much of her career at GlaxoSmithKline in roles to design, execute, and interpret phase 2 and 3 clinical trials and disease management programs.

Debbie has an MPH in epidemiology from the University of Michigan and a BS in biology from Baldwin-Wallace University.

Authored Content


In December 2019, Avalere Health and Endocrine Society launched the first quality measurement set designed to help providers assess how well they identify and care for older adults at greater risk of hypoglycemia – low blood sugar that can be a dangerous complication of diabetes.

Avalere Health and the Endocrine Society launch hypoglycemia clinical tools.

Avalere collaborates with the Endocrine Society and Pottstown Medical Specialists to launch a quality improvement intervention study aimed at addressing care gaps in the identification and management of hypoglycemia in older adults with type 2 diabetes.

This past spring, Avalere and MITRE experts presented “Implementation of the Core Quality Measures Collaborative (CQMC) Core Measure Sets by Public Payers: Successes and Opportunities” at the Pharmacy Quality Alliance (PQA) annual meeting.

Today, Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association published appropriate use criteria (AUC) to guide the use of lumbar puncture (LP) and cerebrospinal fluid (CSF) analysis for use in the diagnosis of Alzheimer’s disease.

Tune into the second podcast in our series where Dr. Leslie Shaw, Professor of Pathology and Laboratory Medicine at the Pearlman School of Medicine at the University of Pennsylvania and Chair of the Workgroup that developed the Alzheimer’s Association’s appropriate use criteria for lumbar puncture and cerebral spinal fluid (CSF) testing in the diagnosis of Alzheimer’s disease, discusses how the Workgroup reviewed an extensive body of research on advances in CSF testing to develop the AUC.

Tune in to our podcast series as we explore the value of the newly released Alzheimer’s Association appropriate use criteria for lumbar puncture and cerebral spinal fluid (CFS) testing in the diagnosis of Alzheimer’s disease. We kick off this series with Dr. Maria Carillo, the Alzheimer Association’s Chief Science Officer and Dr. Jim Hendrix, Director of Global Science Initiatives.

The findings, published in The Journal of Endocrinology & Metabolism, will guide a pilot study to assess interventions to improve the identification and management of diabetes patients at high risk for hypoglycemia.

Avalere published an article this week on ASCO's plan to launch CancerLinQ™.

Listen to Avalere's Debbie Lucas explain the complex world of quality measurement.

In the Calendar Year (CY) 2015 End Stage Renal Disease (ESRD) Prospective Payment System (PPS) final rule released on October 31, the Centers for Medicare & Medicaid Services (CMS) finalized a 2015 base per treatment rate of $239.43, up slightly from $239.02 in CY 2014.

Listen to Debbie Lucas discuss how quality measurement can lead to improvements in the quality of care and the impact on providers.

The use of quality and performance measures in public reporting, value-based purchasing, and alternative payment models is altering clinical practice by providing incentives to improve quality measures performance and provide high-value care. Debbie Lucas helps many stakeholders seek to understand these measures, assess their business impacts, and use the information to guide decision-making.

In the Calendar Year (CY) 2015 End Stage Renal Disease (ESRD) Prospective Payment System (PPS) proposed rule released on July 2, CMS proposes a 2015 base per treatment rate of $239.33, up slightly from $239.02 in CY 2014.

On Feb. 21, CMS enhanced the Physician Compare website to include the addition of quality measures to indicate the performance achieved on a set number of specific metrics.